Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. [electronic resource]
Producer: 20140110Description: 26 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Squamous Cell -- metabolism
- Cetuximab
- Chemoradiotherapy
- Cisplatin -- therapeutic use
- Cyclin-Dependent Kinase Inhibitor p16 -- metabolism
- DNA, Viral -- metabolism
- Disease-Free Survival
- Dose Fractionation, Radiation
- ErbB Receptors -- antagonists & inhibitors
- Female
- Gefitinib
- Head and Neck Neoplasms -- metabolism
- Human papillomavirus 16 -- genetics
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local -- metabolism
- Panitumumab
- Proportional Hazards Models
- Quinazolines -- therapeutic use
- Retrospective Studies
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.